Gracell Biotechnologies, Inc. announced an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2, a tumor-specific marker that is overexpressed in a variety of tumor tissues, including in gastric or gastroesophageal junction cancers.
[Gracell Biotechnologies, Inc.]
7992332
{7992332:nan}
apa
50
1
165769
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
